Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
8(57.1%)
Phase 4
4(28.6%)
Phase 1
1(7.1%)
N/A
1(7.1%)
14Total
Phase 2(8)
Phase 4(4)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT05469659Phase 2Recruiting

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

Role: lead

NCT03755466Phase 2Unknown

Examination of Efficacy and Safety of Baricitinib in RA Patients

Role: lead

NCT03755193Phase 2Recruiting

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Role: lead

NCT02329093Not ApplicableRecruiting

Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA

Role: lead

NCT02156999Phase 4Unknown

Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment

Role: lead

NCT03183557Phase 2Unknown

Efficacy of Zoledronic Acid in Osteoporosis

Role: lead

NCT03315676Phase 2Unknown

Efficacy of Proton Pump Inhibitors in Gastrointestinal Erosions and/or Ulcers

Role: lead

NCT02157012Phase 4Unknown

Evaluation of the Condition of Rheumatoid Arthritis After Treatment

Role: lead

NCT03784261Phase 2Unknown

Usefulness of Non TNF Usage in RA Patients

Role: lead

NCT03702140Phase 2Unknown

Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

Role: lead

NCT03186131Phase 2Unknown

Efficacy of Oral Ibandronate in Osteoporosis

Role: lead

NCT02306187Phase 1Unknown

The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis

Role: lead

NCT02327650Unknown

To Examine Whether or Not the Primary Causes of OA or RA Might be Bone Alterations

Role: lead

NCT02156960Phase 4Unknown

Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Role: lead

NCT02131350Phase 4Completed

Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema

Role: lead

NCT02162277Completed

Therapeutic Strategy in Postmenopausal Women Using Osteoporotic Diagnostic Kits

Role: lead

All 16 trials loaded